The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
The Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services
The biopharmaceutical leader shared its expert perspective at the Equality Lounge at the G20 Summit
These initiatives aim to improve access to healthcare for rare disease patients
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Subscribe To Our Newsletter & Stay Updated
